Department of Paediatrics, Allergy Unit, University of Messina, Messina, Italy.
Paediatric National Healthcare System Turin, Institute of Biomedical Research and Innovation IRIB, Palermo, Turin, Italy.
Pediatr Allergy Immunol. 2020 Nov;31 Suppl 26:46-48. doi: 10.1111/pai.13390.
Atopic dermatitis (AD) is a chronic remitting-relapsing inflammatory skin disorder. Due to the multifactorial pathogenesis, there are numerous therapeutic management approaches, mainly based on symptomatic treatments. In recent years, allergen immunotherapy (AIT) has been progressively advanced as targeted disease-modifying treatment of allergic disease. The most recent guideline from the American Academy of Dermatology concludes that data available do not support its use in AD. The Joint Task Force and The European Academy of Dermatology suggest that clinicians can consider AIT treatment in selected patients characterized by aeroallergen sensitization, prevalently HDM, severe AD, and clinical exacerbation after exposure to the causative allergen. Nevertheless, its role in AD is still under debate, especially in children.
特应性皮炎（AD）是一种慢性复发性炎症性皮肤病。由于发病机制复杂，有许多治疗管理方法，主要基于对症治疗。近年来，过敏原免疫疗法（AIT）作为过敏疾病的靶向疾病修正治疗已逐步得到发展。美国皮肤病学会的最新指南得出结论，现有数据不支持其在 AD 中的应用。联合工作组和欧洲皮肤病学会建议，对于以空气过敏原致敏、主要为 HDM、严重 AD 和接触致敏原后临床恶化的患者，临床医生可以考虑 AIT 治疗。然而，AIT 在 AD 中的作用仍存在争议，尤其是在儿童中。
